Abstract
Overview
Introduction
The current epilepsy market boasts a wide range of treatment options and has
recently reached a state of maturity. The market value across the 7MM grew by
just 2.3% from 2005 to $3.2 billion in 2006. However, imminent change to the
market in the near to mid term will be brought about by the occurrence of key
patent expiries and new drugs launches.
Scope
- This report focuses on drugs used to treat epilepsy, with indication- and
country-specific sales value and volume forecasts to 2016.
- Assessment of current and future opportunities and threats in the epilepsy
market across the 7MMs and in individual regions.
- Identification of future market events expected to impact
epilepsy-specific anticonvulsant drug revenues over the next decade.
- Case study analysis of successful lifecycle management strategies and
provision of key recommendations to ensure revenue growth.
Report Highlights
Despite advances in epilepsy treatment over the past 15 years, the efficacy of
current anticonvulsants remains limited, with approximately 20-30% of patients
continuing to suffer from refractory seizures. As such, in an increasingly
crowded market, targeting refractory epilepsy patients continues to present a
potentially lucrative opportunity.
Focusing on epilepsy rather than diversifying into other secondary CNS
indications has played a pivotal role for UCB in ensuring Keppra' s market
leadership and ongoing strong uptake. Demonstrating a solid commitment to the
disease will be viewed favorably by neurologists and will promote brand
loyalty. This, in turn will provide long-term growth.
Keppra' s pediatric epilepsy indication expansions over the past 2 years have
served to expand its patient base. In view of the high prevalence of childhood
epilepsy and high level of unmet need in this patient group, gaining approval
in the pediatric population remains an attractive means of increasing revenue
and strengthening brand loyalty.
Reasons to Purchase
- Quantify the future size of the epilepsy market, in terms of prescription
volume and value, in each of the seven major markets.
- Assess the impact of future events such as patent expiries, indication
expansions, and new product launches on the sales of key marketed brands.
- Identify key lifecycle management strategies and market opportunities that
can ensure growth in the increasingly competitive epilepsy market.
View Cart
